Misuse and overuse of antimicrobials is one of the world’s most pressing public health problems. Infectious organisms adapt to the antimicrobials designed to kill them, making the drugs ineffective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of an infection. Improving the way we prescribe and use antibiotics, or “antibiotic stewardship,” is critical to effectively treat infections, protect patients from harms caused by unnecessary antibiotic use, and combat antibiotic resistance.
Antimicrobial stewardship provides critical diagnostic information to make better drug choices, leading to fewer adverse effects and reducing the cost of treatment. The antimicrobial stewardship report powered by Arkstone Medical Solutions is based on scientific evidence. It helps select the best drug choices, optimum doses, shorter treatment length, and best administration route.
In the case of multidrug-resistant organisms, antimicrobial, stewardship-based treatment options can save lives, reduce hospitalization cost, drug toxicity, and the duration of treatment. The goal of antimicrobial stewardship is to select the best drug for treating a wild pathogen organism. Without proper antimicrobial stewardship, multiple drug usage can result in resistance. Multidrug-resistant organisms or superbugs are a global challenge; according to CDC, more than 2 million U.S. citizens are infected with MDRO multidrug resistant pathogens, resulting in approximately 23,000 deaths.